-
公开(公告)号：US20050119202A1
公开(公告)日：2005-06-02
申请号：US10493686
申请日：2002-10-25
IPC分类号： C12N15/09 , A61K9/127 , A61K9/50 , A61K9/51 , A61K31/7105 , A61K31/713 , A61K38/00 , A61P31/14 , C07K14/18 , C07K14/82 , C12N15/113 , C12N15/40 , C12N15/51 , C12N15/88 , A61K48/00 , C07H21/02
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/14 , C12N2310/53
摘要： The invention concerns a medicament to treat a fibrotic disease, wherein the medicament contains a double-stranded ribonucleic acid (dsRNA) that is suitable for inhibiting by RNA interference the expression of a gene that is involved in the formation of extracellular matrix.
摘要翻译： 本发明涉及治疗纤维化疾病的药物，其中药物含有双链核糖核酸（dsRNA），其适用于通过RNA干扰参与细胞外基质形成的基因的表达。
-
2.发明授权公开(公告)号：US07473525B2
公开(公告)日：2009-01-06
申请号：US10384260
申请日：2003-03-07
申请人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
发明人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
CPC分类号： C12N15/113 , C12N15/1131 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
摘要翻译： 本发明涉及用于抑制抗凋亡基因表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的互补RNA链，其至少与至少 凋亡基因的一部分，如Bcl基因。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由抗凋亡基因表达引起的疾病的方法; 以及抑制细胞中抗凋亡基因表达的方法。
-
公开(公告)号：US08273870B2
公开(公告)日：2012-09-25
申请号：US13177316
申请日：2011-07-06
申请人： Roland Kreutzer , Stefan Limmer , Matthias John
发明人： Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号： C07H21/04
CPC分类号： C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译： 本发明涉及用于抑制突变基因表达的双链核糖核酸（dsRNA），其包含第一链，该第一链具有与至少部分至少部分的RNA转录物的至少一部分互补的互补区 突变靶基因和与第一链互补或基本上互补的dsRNA的第二链。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达，以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法，以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号：US20110287090A1
公开(公告)日：2011-11-24
申请号：US13177316
申请日：2011-07-06
申请人： Roland Kreutzer , Stefan Limmer , Matthias John
发明人： Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号： A61K31/713 , A61P35/02 , A61P35/00 , C07H21/02 , A61K9/127
CPC分类号： C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译： 本发明涉及用于抑制突变基因表达的双链核糖核酸（dsRNA），其包含第一链，该第一链具有与至少部分至少部分的RNA转录物的至少一部分互补的互补区 突变靶基因和与第一链互补或基本上互补的dsRNA的第二链。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达，以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法，以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号：US20100291194A1
公开(公告)日：2010-11-18
申请号：US12817009
申请日：2010-06-16
申请人： Roland Kreutzer , Stefan Limmer , Matthias John
发明人： Roland Kreutzer , Stefan Limmer , Matthias John
CPC分类号： C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译： 本发明涉及用于抑制突变基因表达的双链核糖核酸（dsRNA），其包含互补RNA链，其具有与突变基因的一部分基本上互补的互补区，并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达，以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法，以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号：US20080194512A1
公开(公告)日：2008-08-14
申请号：US11959936
申请日：2007-12-19
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
公开(公告)号：US07348314B2
公开(公告)日：2008-03-25
申请号：US10384512
申请日：2003-03-07
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
公开(公告)号：US07994309B2
公开(公告)日：2011-08-09
申请号：US12817009
申请日：2010-06-16
申请人： Roland Kreutzer , Stefan Limmer , Matthias John
发明人： Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号： C07H21/04
CPC分类号： C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译： 本发明涉及用于抑制突变基因表达的双链核糖核酸（dsRNA），其包含互补RNA链，其具有与突变基因的一部分基本上互补的互补区，并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达，以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法，以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号：US07763590B2
公开(公告)日：2010-07-27
申请号：US10384463
申请日：2003-03-07
申请人： Roland Kreutzer , Stefan Limmer , Matthias John
发明人： Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号： A61K48/00
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译： 本发明涉及用于抑制突变基因表达的双链核糖核酸（dsRNA），其包含互补RNA链，其具有与突变基因的一部分基本上互补的互补区，并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达，以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法，以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号：US20130064879A1
公开(公告)日：2013-03-14
申请号：US13594150
申请日：2012-08-24
IPC分类号： A61K31/713 , A61K9/127 , A61P31/14 , C07H21/02
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译： 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸（dsRNA），并且其基本上与3'非翻译区（3'-UTR）的至少一部分相同 （+）链RNA病毒，例如HCV，以及包含dsRNA的药物组合物，以及药学上可接受的载体。 药物组合物可用于治疗由（+）链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.029 秒)